N'ime ọmụmụ ihe OASIS Phase IIIa, semaglutide ọnụ 50 mg otu ugboro kwa ụbọchị nyere ndị okenye oke ibu ma ọ bụ buru oke ibu aka ida 15.1% nke ahụ ha, ma ọ bụ 17.4% ma ọ bụrụ na ha na-agbaso ọgwụgwọ, Novo Nordisk na-akọ.Ụdị 7 mg na 14 mg nke semaglutide ọnụ ka akwadoro ugbu a maka ụdị ọrịa shuga 2 n'okpuru aha Rybelsus.
N'ikwekọ na ọmụmụ ihe gara aga, ọmụmụ Bavaria chọpụtara na nchoputa COVID-19 jikọtara ya na mmụba nke ụdị ọrịa shuga 1 na ụmụaka.(American Medical Association)
Ndị ọrụ mgbochi United States Preventive Services Task Force (USPSTF) na-achọ ugbu a echiche ọha na eze na atụmatụ atụmatụ ya maka nyocha banyere ihe mgbochi oke ibu iji gbochie ọrịa na ọnwụ metụtara oke ibu na ndị okenye.
E jiri ya tụnyere ndị inyom na-enweghị ọrịa shuga, ụmụ nwanyị ndị nọ n'etiti ndị nwere ọrịa shuga (ọkwa shuga na-ebu ọnụ n'etiti 100 na 125 mg/dL) bụ 120% nwere ike inwe mgbaji n'oge na mgbe mgbanwe nke menopausal gasịrị.( netwọk JAMA mepere emepe)
Valbiotis kwuputara na Totum 63, nchikota nyocha nke sitere na ihe ọkụkụ ise, belatara ọkwa glucose ọbara na-ebu ọnụ nke ukwuu na ndị ọrịa nwere ọrịa shuga na-arịa ọrịa shuga na ụdị ọrịa shuga 2 n'oge a na-agwọghị ya na usoro II/III REVERSE-IT.
Ọgwụ semaglutide na-efunahụ ibu (Wegovy) nwere ike belata ohere nke ọrịa obi, dịka nsonaazụ nnwale mbụ siri dị.(Reuters)
Kristen Monaco bụ onye ode akwụkwọ ọrụ ọkachamara na akụkọ endocrinology, psychiatry na nephrology.Ọ dabere na ụlọ ọrụ New York kemgbe 2015.
Ihe ndị dị na webụsaịtị a bụ maka ebumnuche ozi naanị na ọ bụghị nnọchi maka ndụmọdụ ahụike, nyocha, ma ọ bụ ọgwụgwọ sitere n'aka onye na-ahụ maka ahụike tozuru oke.© 2005–2022 MedPage Taa, LLC, ụlọ ọrụ Ziff Davis.Ikike niile echekwabara.Medpage Today bụ otu n'ime ụghalaahia edenyere nke gọọmentị etiti nke MedPage Today, LLC na ndị ọzọ agaghị eji ya na-enwetaghị ikike ozugbo.
Oge nzipu: Jun-15-2023